A Korean Post-Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With EGFR-expressing, KRAS Wild-type Metastatic Colorectal Cancer
This is a post marketing surveillance (PMS), prospective study to collect safety information
from more than 600 subjects with epidermal growth factor receptor (EGFR)-expressing,
V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type metastatic colorectal
cancer (mCRC) treated with Erbitux as final evaluable cases. This PMS is requested by the
Korean Regulatory Authorities because after removal of an orphan drug in Korea, there is a
requirement to investigate more than 600 patients during six years, to continue monitoring
and provide further information about safety and toxicity in clinical practice.
This PMS study is planned to be conducted within 6 years from the removal date of orphan
drug in approximately 50 institutions in Korea.
The objective of the study is to analyse the safety and efficacy information on the use of
Erbitux in the market and factors affecting its safety and efficacy.
- To obtain safety information on the use of Erbitux in subjects with mCRC in terms of
frequency and severity of adverse events (AEs)
- To gather clinical efficacy information of the treatment
During the PMS period, each subject's background, medical history (surgery, radiotherapy),
Erbitux treatment status, concurrent medication, response evaluation, status and reason of
discontinuation, all AEs (regardless of the causal relationship to Erbitux), and abnormal
results of laboratory tests will be collected from the start of treatment with Erbitux until
progressive disease, Erbitux-related intolerable toxicities, death, or withdrawal of Erbitux
treatment (whichever occurs first). The primary endpoint, the safety evaluation will be
based on all cases treated with Erbitux having received at least one dose. However, for
efficacy evaluation, 12 weeks of treatment have to be applied to each subject.
Erbitux will be prescribed to mCRC subjects according to the approved national label as in
routine clinical practice, under the supervision of an investigator experienced in the use
of antineoplastic medicinal products. Prior to the first infusion, subjects will receive
pre-medication with an antihistamine and a corticosteroid. The initial dose of Erbitux is
400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered
intravenously via in-line filtration with an infusion pump, gravity drip, or a syringe pump.
The recommended infusion period for the initial dose is 120 minutes and for the subsequent
weekly doses is 60 minutes with the maximum infusion rate not exceeding 10 mg/min,
equivalent to 5 ml/min of Erbitux 2 mg/ml.
Observational Model: Case-Only, Time Perspective: Prospective
Incidence and severity of all adverse events, regardless of the causal relationship to Erbitux
Initial treatment period to final treatment period
Korea: Food and Drug Administration
EMR 62202-509 (EMR 62202-551)